hydroxyurea has been researched along with zalcitabine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Plagemann, PG; Woffendin, C | 1 |
| Chokekuchai, S; Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Grange, JM; Hamedi-Sangsari, F; Malley, SD; Vila, JR | 1 |
| Auclair, C; Carteau, S; Goulaouic, H; Mouscadet, JF; Subra, F | 1 |
| Agarwal, RP; He, J | 1 |
| Chiang, Y; Drake, RR; Govindarajan, R; Hume, SD; Krisa, S; McMasters, R; Munshi, NC; Rechtin, TM; Saylors, RL | 1 |
| Davis, C; Heredia, A; Redfield, R | 1 |
| Mascolini, M | 1 |
| Torres, G | 1 |
23 other study(ies) available for hydroxyurea and zalcitabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes.
Topics: Animals; Blood Proteins; Carrier Proteins; Dipyridamole; Erythrocytes; Humans; Hydroxyurea; Leukemia, Experimental; Membrane Proteins; Mice; Nucleoside Transport Proteins; Permeability; Solubility; Structure-Activity Relationship; Thioinosine; Uridine; Zalcitabine | 1989 |
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
Topics: Adenosine Kinase; Cells, Cultured; Didanosine; DNA Replication; Drug Synergism; HIV-1; Humans; Hydroxyurea; Phosphorylation; Proviruses; Uridine Kinase; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Dideoxynucleosides; Drug Synergism; HIV-1; Humans; Hydroxyurea; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Topics: Antiviral Agents; Asparagine; Aspartic Acid; Cell Survival; Cells, Cultured; Didanosine; Drug Synergism; HIV Infections; Humans; Hydroxyurea; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Potentiation of 2',3'-dideoxycytidine (ddC) by hydroxyurea and thymidine on the Moloney murine leukemia virus (MoMLV) early replicative steps.
Topics: 3T3 Cells; Animals; Drug Synergism; Hydroxyurea; Mice; Moloney murine leukemia virus; Thymidine; Transcription, Genetic; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Effect of hydroxyurea on 2',3'-dideoxycytidine activation.
Topics: Biotransformation; Cell Line; Humans; Hydroxyurea; Zalcitabine | 1994 |
Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes.
Topics: Acyclovir; Cell Line; Dose-Response Relationship, Drug; Ganciclovir; Genetic Therapy; Growth Inhibitors; Herpesvirus 1, Human; HIV-1; Humans; Hydroxyurea; Nucleosides; Stavudine; Substrate Specificity; T-Lymphocytes; Thymidine Kinase; Zalcitabine; Zidovudine | 1997 |
Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Topics: Cell Division; Didanosine; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; HIV-1; Humans; Hydroxyurea; Leukocytes, Mononuclear; Macrophages; Nucleosides; Resveratrol; Stilbenes; Virus Replication; Zalcitabine; Zidovudine | 2000 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Indinavir; Interleukin-2; Lamivudine; Mutation; Pyridines; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Leukocytes, Mononuclear; Virus Replication; Zalcitabine; Zidovudine | 1995 |